Acrodermatitis chronica atrophicans

Jump to navigation Jump to search
Acrodermatitis chronica atrophicans
ICD-10 L90.4
ICD-9 701.8
DiseasesDB 32940

WikiDoc Resources for Acrodermatitis chronica atrophicans

Articles

Most recent articles on Acrodermatitis chronica atrophicans

Most cited articles on Acrodermatitis chronica atrophicans

Review articles on Acrodermatitis chronica atrophicans

Articles on Acrodermatitis chronica atrophicans in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Acrodermatitis chronica atrophicans

Images of Acrodermatitis chronica atrophicans

Photos of Acrodermatitis chronica atrophicans

Podcasts & MP3s on Acrodermatitis chronica atrophicans

Videos on Acrodermatitis chronica atrophicans

Evidence Based Medicine

Cochrane Collaboration on Acrodermatitis chronica atrophicans

Bandolier on Acrodermatitis chronica atrophicans

TRIP on Acrodermatitis chronica atrophicans

Clinical Trials

Ongoing Trials on Acrodermatitis chronica atrophicans at Clinical Trials.gov

Trial results on Acrodermatitis chronica atrophicans

Clinical Trials on Acrodermatitis chronica atrophicans at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Acrodermatitis chronica atrophicans

NICE Guidance on Acrodermatitis chronica atrophicans

NHS PRODIGY Guidance

FDA on Acrodermatitis chronica atrophicans

CDC on Acrodermatitis chronica atrophicans

Books

Books on Acrodermatitis chronica atrophicans

News

Acrodermatitis chronica atrophicans in the news

Be alerted to news on Acrodermatitis chronica atrophicans

News trends on Acrodermatitis chronica atrophicans

Commentary

Blogs on Acrodermatitis chronica atrophicans

Definitions

Definitions of Acrodermatitis chronica atrophicans

Patient Resources / Community

Patient resources on Acrodermatitis chronica atrophicans

Discussion groups on Acrodermatitis chronica atrophicans

Patient Handouts on Acrodermatitis chronica atrophicans

Directions to Hospitals Treating Acrodermatitis chronica atrophicans

Risk calculators and risk factors for Acrodermatitis chronica atrophicans

Healthcare Provider Resources

Symptoms of Acrodermatitis chronica atrophicans

Causes & Risk Factors for Acrodermatitis chronica atrophicans

Diagnostic studies for Acrodermatitis chronica atrophicans

Treatment of Acrodermatitis chronica atrophicans

Continuing Medical Education (CME)

CME Programs on Acrodermatitis chronica atrophicans

International

Acrodermatitis chronica atrophicans en Espanol

Acrodermatitis chronica atrophicans en Francais

Business

Acrodermatitis chronica atrophicans in the Marketplace

Patents on Acrodermatitis chronica atrophicans

Experimental / Informatics

List of terms related to Acrodermatitis chronica atrophicans

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]

Synonyms and keywords: Pick-Herxheimer disease

Overview

Acrodermatitis chronica atrophicans (ACA) is a skin rash indicative of the third or late stage of European Lyme borreliosis.

ACA is a dermatological condition that takes a chronically progressive course and finally leads to a widespread atrophy of the skin. Involvement of the peripheral nervous system is often observed, specifically polyneuropathy.

Historical Perspective

The first record of ACA was made in 1883 in Breslau, Germany, where a physician named Alfred Buchwald first delineated it.

Herxheimer and Hartmann described it in 1902 as a "tissue paper" like cutaneous atrophy.

Pathophysiology

This progressive skin process is due to the effect of continuing active infection with the spirochete Borrelia afzelii. B afzelii is the predominant pathophysiology, but may not be the exclusive, etiologic agent of ACA. Borrelia garinii, has also been detected.

Microscopic Pathology

  • Light and electron microscopic study if the skin biopsy shows degeneration of the elastica and collagen fibers.[1]

Natural History, Complications and Prognosis

The course of ACA is long-standing, from a few to several years, and it leads to extensive atrophy of the skin and, in some patients, to the limitation of upper and lower limb joint mobility.

The outlook is good if the acute inflammatory stage of ACA is treated adequately. The therapeutic outcome is difficult to assess in patients with the chronic atrophic phase, in which many changes are only partially reversible.

Diagnosis

Symptoms

The rash caused by ACA is most evident on the extremities or limbs beginning with an inflammatory stage with bluish red discoloration and cutaneous swelling and concluding several months or years later with an atrophic phase. Sclerotic skin plaques may also develop.

As ACA progresses the skin begins to wrinkle.

Laboratory Findings

Physicians should use serologic and histologic examination to confirm the diagnosis of ACA.

Treatment

Treatment consists of antibiotics including doxycycline and penicillin for up to four weeks in the acute case.

See also

External links


Template:WikiDoc Sources

  1. de Koning J, Tazelaar DJ, Hoogkamp-Korstanje JA, Elema JD (1995). "Acrodermatitis chronica atrophicans: a light and electron microscopic study". J. Cutan. Pathol. 22 (1): 23–32. PMID 7751475. Unknown parameter |month= ignored (help)